Ordastobart

奥达苏拜单抗

Report date: 2026/04/17 20:02:02

Base Information

Drug NameOrdastobart
Drug Alias NameHexavalent OX40 agonist antibodyINBRX-106ES-102ES102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 agonists
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaUnited States +[15] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInhibrx
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesElpiscience (Shanghai) Biopharma LtdInhibrx Biosciences IncElpiscience Biopharma Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A